A meta-analysis of the effectiveness and safety of safinamide for levodopa-induced motor complications in Parkinson's disease.

Li, J; Zhang, J; Meng, P

A meta-analysis of the effectiveness and safety of safinamide for levodopa-induced motor complications in Parkinson's disease.

Li, J

Zhang, J Meng, P

Permalink

Publisher:: TAYLOR & FRANCIS LTD
Publication Type:: Journal Article
Citation:: Biotechnol Genet Eng Rev, 2023, ahead-of-print, (ahead-of-print), pp. 1-12
Issue Date:: 2023-05-26

Closed Access

	Filename	Description	Size
	A meta-analysis of the effectiveness and safety of safinamide for levodopa-induced motor complications in Parkinson s disease.pdf	Published version	969.29 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Li, J https://orcid.org/0000-0002-3584-6765
dc.contributor.author	Zhang, J
dc.contributor.author	Meng, P
dc.date.accessioned	2024-03-17T22:22:59Z
dc.date.available	2024-03-17T22:22:59Z
dc.date.issued	2023-05-26
dc.identifier.citation	Biotechnol Genet Eng Rev, 2023, ahead-of-print, (ahead-of-print), pp. 1-12
dc.identifier.issn	0264-8725
dc.identifier.issn	2046-5556
dc.identifier.uri	http://hdl.handle.net/10453/176817
dc.description.abstract	To systematically evaluate the effectiveness and safety of safinamide in the treatment of levodopa-induced motor complications of Parkinson's disease (PD). A search strategy was developed and PubMed, Embase, Web of Science, Cochrane Library, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and WanFang Data were searched to find randomized controlled trials on the treatment of PD motor complications caused by levodopa with safinamide. A manual reference search was conducted for articles published until June 2022 to independently screen references, extract data, and evaluate the risk of bias in the included studies. RevMan 5.3 software was utilized to analyze the data. A total of 5 randomized controlled trials with 2061 PD patients were included, containing 1277 patients in the safinamide group (trial group) and 784 patients in the control group. Meta-analysis results exhibited that regarding effectiveness, the duration of continuous optimal drug effect without dyskinesia (On-time) of the 50 mg trial group was longer than that of the control group. The On-time of the 100 mg trial group was longer than that of the control group.The improvement of the Unified Parkinson's Disease Rating Scale Part III (UPDRSIII) score in the 50 mg trial group was better than that in the control group. The improvement of the UPDRSIII score of the 100 mg trial group was better than that of the control group.There was no significant difference in the incidence of adverse events between the two groups. Safinamide is effective and safe in the treatment of PD motor complications caused by levodopa.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	TAYLOR & FRANCIS LTD
dc.relation.ispartof	Biotechnol Genet Eng Rev
dc.relation.isbasedon	10.1080/02648725.2023.2215045
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	06 Biological Sciences, 09 Engineering, 10 Technology
dc.subject.classification	Biotechnology
dc.subject.classification	3001 Agricultural biotechnology
dc.subject.classification	3106 Industrial biotechnology
dc.subject.classification	3206 Medical biotechnology
dc.title	A meta-analysis of the effectiveness and safety of safinamide for levodopa-induced motor complications in Parkinson's disease.
dc.type	Journal Article
utslib.citation.volume	ahead-of-print
utslib.location.activity	England
utslib.for	06 Biological Sciences
utslib.for	09 Engineering
utslib.for	10 Technology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	closed_access	*
dc.date.updated	2024-03-17T22:22:58Z
pubs.issue	ahead-of-print
pubs.publication-status	Published online
pubs.volume	ahead-of-print
utslib.citation.issue	ahead-of-print

Abstract:

To systematically evaluate the effectiveness and safety of safinamide in the treatment of levodopa-induced motor complications of Parkinson's disease (PD). A search strategy was developed and PubMed, Embase, Web of Science, Cochrane Library, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and WanFang Data were searched to find randomized controlled trials on the treatment of PD motor complications caused by levodopa with safinamide. A manual reference search was conducted for articles published until June 2022 to independently screen references, extract data, and evaluate the risk of bias in the included studies. RevMan 5.3 software was utilized to analyze the data. A total of 5 randomized controlled trials with 2061 PD patients were included, containing 1277 patients in the safinamide group (trial group) and 784 patients in the control group. Meta-analysis results exhibited that regarding effectiveness, the duration of continuous optimal drug effect without dyskinesia (On-time) of the 50 mg trial group was longer than that of the control group. The On-time of the 100 mg trial group was longer than that of the control group.The improvement of the Unified Parkinson's Disease Rating Scale Part III (UPDRSIII) score in the 50 mg trial group was better than that in the control group. The improvement of the UPDRSIII score of the 100 mg trial group was better than that of the control group.There was no significant difference in the incidence of adverse events between the two groups. Safinamide is effective and safe in the treatment of PD motor complications caused by levodopa.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/176817